695 related articles for article (PubMed ID: 28807747)
1. Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy.
Hegde JV; Demanes DJ; Veruttipong D; Raince J; Park SJ; Raman SS; Nickols NG; King CR; Kishan AU; Steinberg ML; Kamrava M
Brachytherapy; 2017; 16(6):1106-1112. PubMed ID: 28807747
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment Multiparametric Magnetic Resonance Imaging Findings Are More Accurate Independent Predictors of Outcome Than Clinical Variables in Localized Prostate Cancer.
Gomez-Iturriaga A; Casquero F; Pijoan JI; Crook J; Urresola A; Ezquerro A; Villeirs GM; Bossi A; Cacicedo J; Buchser D; Bilbao P
Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1172-1178. PubMed ID: 29861199
[TBL] [Abstract][Full Text] [Related]
3. Impact of five-tiered Gleason grade groups on prognostic prediction in clinical stage T3 prostate cancer undergoing high-dose-rate brachytherapy.
Tsumura H; Ishiyama H; Tabata KI; Katsumata H; Kobayashi M; Ikeda M; Kurosaka S; Fujita T; Kitano M; Satoh T; Yanagisawa N; Hayakawa K; Iwamura M
Prostate; 2017 Nov; 77(15):1520-1527. PubMed ID: 28905446
[TBL] [Abstract][Full Text] [Related]
4. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
[TBL] [Abstract][Full Text] [Related]
5. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
[TBL] [Abstract][Full Text] [Related]
6. Stage T3b prostate cancer diagnosed by seminal vesicle biopsy and treated with neoadjuvant hormone therapy, permanent brachytherapy and external beam radiotherapy.
Stone NN; Stock RG
BJU Int; 2019 Feb; 123(2):277-283. PubMed ID: 29956864
[TBL] [Abstract][Full Text] [Related]
7. A Pooled Analysis of Biochemical Failure in Intermediate-risk Prostate Cancer Following Definitive Stereotactic Body Radiotherapy (SBRT) or High-Dose-Rate Brachytherapy (HDR-B) Monotherapy.
Hegde JV; Collins SP; Fuller DB; King CR; Demanes DJ; Wang PC; Kupelian PA; Steinberg ML; Kamrava M
Am J Clin Oncol; 2018 May; 41(5):502-507. PubMed ID: 27322703
[TBL] [Abstract][Full Text] [Related]
8. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.
Joseph N; Taylor C; O'Hara C; Choudhury A; Elliott T; Logue J; Wylie J
Radiother Oncol; 2016 Nov; 121(2):299-303. PubMed ID: 28029404
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancer.
Agarwal M; Chhabra AM; Amin N; Braccioforte MH; Molitoris JK; Moran BJ
Brachytherapy; 2018; 17(6):882-887. PubMed ID: 30143400
[TBL] [Abstract][Full Text] [Related]
10. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of seminal vesicle invasion on preoperative multi-parametric magnetic resonance imaging in pathological stage T3b prostate cancer.
Kim JK; Lee HJ; Hwang SI; Choe G; Hong SK
Sci Rep; 2020 Mar; 10(1):5693. PubMed ID: 32231265
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment multiparametric MRI is independently associated with biochemical outcome in men treated with radiation therapy for prostate cancer.
Kauffmann G; Arif F; Patel P; Oto A; Liauw SL
Urol Oncol; 2018 Oct; 36(10):471.e11-471.e18. PubMed ID: 30122344
[TBL] [Abstract][Full Text] [Related]
13. Biopsy and implantation of the seminal vesicles.
Stone NN; Skouteris VM; Stock RG
Brachytherapy; 2012; 11(5):334-40. PubMed ID: 22305509
[TBL] [Abstract][Full Text] [Related]
14. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
15. Prospective study of HDR brachytherapy (BT), external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT): 10-years experience of an MRI-guided approach.
Gomez-Iturriaga A; Zaragoza L; Valverde I; Perez Azorin F; Santos-Zorrozua B; Guerrero JA; Couñago F; Cacicedo J; Marban M; Santana S; Mascarell C; Novo E; Fernandez R; Garcia-Olaverri J; Urresola A; Ezquerro A; Büchser D
Radiother Oncol; 2024 Jan; 190():110024. PubMed ID: 37995851
[TBL] [Abstract][Full Text] [Related]
16. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience.
Sylvester JE; Blasko JC; Grimm PD; Meier R; Malmgren JA
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):944-52. PubMed ID: 14575824
[TBL] [Abstract][Full Text] [Related]
17. Gleason 7 prostate cancer treated with low-dose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure.
Stock RG; Berkowitz J; Blacksburg SR; Stone NN
BJU Int; 2012 Nov; 110(9):1257-61. PubMed ID: 22571680
[TBL] [Abstract][Full Text] [Related]
18. [Outcomes and predictors of T3a prostate cancer treated by permanent interstitial brachytherapy combined with external radiotherapy and hormone therapy].
Mai Z; Yan W; Li H; Zhou Y; Zhou Z; Chen J
Zhonghua Wai Ke Za Zhi; 2014 Oct; 52(10):765-70. PubMed ID: 25573217
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment endorectal coil magnetic resonance imaging findings predict biochemical tumor control in prostate cancer patients treated with combination brachytherapy and external-beam radiotherapy.
Riaz N; Afaq A; Akin O; Pei X; Kollmeier MA; Cox B; Hricak H; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):707-11. PubMed ID: 22425220
[TBL] [Abstract][Full Text] [Related]
20. Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy.
Kestin LL; Goldstein NS; Vicini FA; Martinez AA
J Urol; 2002 Nov; 168(5):1994-9. PubMed ID: 12394693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
